USHER III INITIATIVE

Developing a drug therapy for both vision and hearing loss in individuals diagnosed with Usher III
Discovery of Usher Syndrome

Named for Charles Usher, whose 1914 study of the pathology and transmission of the disease identified its hereditary nature.
Finger Test to Assess Peripheral Vision
Tunnel Vision
A Pioneer in Inherited Retinal Diseases

• Discovered that ERGs can detect defects in photoreceptors up to 10 years prior to onset of RP
• Discovered first genetic defects associated with RP
• Professor of Ophthalmology at Harvard Medical School (1968-2017)
• Founding Director of the Berman-Gund Laboratory for the Study of Retinal Degenerations at Mass. Eye and Ear

Dr. Eliot Berson
<table>
<thead>
<tr>
<th></th>
<th>Type 1</th>
<th>Type 2</th>
<th>Type 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hearing</strong></td>
<td>Profound hearing loss or deafness at birth.</td>
<td>Moderate to severe hearing loss at birth.</td>
<td>Progressive hearing loss in childhood or early teens.</td>
</tr>
<tr>
<td><strong>Vision</strong></td>
<td>Decreased night vision by age 10, progressing to severe vision loss by midlife.</td>
<td>Decreased night vision by adolescence, progressing to severe vision loss by midlife.</td>
<td>Varies in severity and age of onset; night vision problems often begin in teens and progress to severe vision loss by midlife.</td>
</tr>
<tr>
<td>(vestibular</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>function)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

There are many variations in the clinical symptoms of Usher syndrome, therefore the classification of Usher types 1, 2, and 3 must be supported by genetic testing.
Richard and Cindy Elden
Clarin-1 (CLRN1)

• Research shows that the same pathology is likely responsible for the auditory and visual loss associated with USH3: defects in the CLRN1 gene, which encodes the CLRN1 protein

• CLRN1 protein is found in the retina and hair cells in the inner ear, and likely plays a critical role in maintaining the structure of these sensory cells

• There are 15 known pathogenic mutations in CLRN1. The two most common are: p.Y176X and p.N48K
Clarin-1 Protein Structure Showing Amino Acid Chain and Glycosylation Site
Localization of *Clarin-1* Protein

Normal protein (red) covers the cell surface bound to the plasma membrane

Mutated protein (red) only present inside the cell (yellow)
Gene Therapy

• Relatively new technology; still being refined
• Injecting a viral vector into the nucleus of the cell and modifying the mutated *clarin-1* gene in the inner ear successfully preserved hair cells in the cochlea in USH3 mouse models
• Few clinics have the capability to inject into the ear and the eye directly, and this procedure can be uncomfortable for patients and lead to serious problems, like infection
• Localized injections do not address system-wide issues
• Has potential to permanently eliminate the problem, but long-term side effects are still unknown
Small Molecule Development

• First developed beginning in 1928 with the discovery of penicillin
• Has been used to develop countless drugs in circulation today
• There is significant precedent for the pathway to gaining regulatory approval and determining clinical safety
• When translated into drug therapies, small molecules can often be administered orally
BF844—Our Novel Compound

- A protein stabilizer with selectivity for CLRN1
- Identified via a high throughput screening of over 5,000 molecules
- Impact on hearing loss was measured using the auditory evoked brain responses in transgenic mice
- BF844 was administered intraperitoneally once daily at 30 mg/kg
- Mice were observed at postnatal days 22, 46 and 55
BF844 was Effective in Mitigating Hearing Loss in USH3 Mouse Model

Untreated mice require 100 db to respond

treated mice require 35 db to respond
The Benefits of BF844

• Restored the auditory sensitivity of USH3 mice to the same decibel level as healthy mice
• Designed as systemic treatment to address both sensory losses
• Rescues mutations in rhodopsin
• Administered orally
• Crosses blood-cochlear and blood-retinal barriers
Clinicians on our Board of Directors

Dr. David Saperstein, M.D.
Partner Physician, Proliance Retina; Co-Founder & Chief Medical Officer, Retinagenix; Co-Founder & CEO, Zumedix, LP

Dr. Paul Sternberg Jr., M.D.
G.W. Hale Professor & Chairman, Department of Ophthalmology and Visual Sciences, Vanderbilt University

Dr. Julia Hayes, M.D.
Medical Oncologist, Dana-Farber Cancer Institute, St. Elizabeth Medical Center; Assistant Professor in Medicine, Harvard Medical School
Selected Scientific Advisory Board Members

Dr. David Birch, Ph.D.
Scientific Director, Retina Foundation of the Southwest

Dr. Anthony P. Adamis, M.D.
VP, Global Head of Ophthalmology, Genentech, Inc

Dr. Lawrence Lustig, M.D.
Howard W. Smith Professor & Chair, Department of Otolaryngology—Head & Neck Surgery, Columbia University Medical Center, New York Presbyterian Hospital

Dr. Eeva-Marja Sankila, M.D., Ph.D.
Clinical Consultant in Ophthalmology, Blueprint Genetics
Next Steps

• Complete remaining toxicity tests prior to IND submission
• Scale up material production to meet GMP standards
• Design clinical trials
• On average it costs $2 billion dollars to develop a small molecule into a drug therapy
What You Can Do

• Get genotyped and register with the Usher Coalition
• Support our research
• Sign up for clinical trials
• Get in touch with us by emailing georgia@usheriii.org

We want to connect with you!
Learn More

To learn more about USH3 and the Initiative, please visit our website www.usheriiii.org, where you can read articles and interviews, get involved, and donate directly to USH3 research.

Thank you to our incredible staff: Dr. Mahdi Farhan (Chief Scientific Officer); Tracey Fletcher, (General Counsel and Managing Director) and Georgia Horn (Development Director and Project Manager)